Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQ tree SLIT-tablet in children and adolescents with tree pollen allergic rhinoconjunctivitis
2020-004372-17Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic conjunctivitis (AC) and allergic rhinoconjunctivitis (ARC) comparing SQ tree SLIT-tablet with Placebo (2 arms). Primary endpoint: Average TCS during the BPS. Started Dec 2020; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2020-004372-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004372-17.